Paymentus to Report Second Quarter 2025 Earnings Results and Host Webcast on August 4, 2025
The Company will discuss the results in a live webcast at 5 p.m. Eastern Time on August 4, 2025.
A replay of the webcast will be available for one year following its conclusion and accessible on the Paymentus website.
About Paymentus
Paymentus is a leading provider of cloud-based bill payment technology and solutions for more than 2,500 billers and financial institutions across North America. Our omni-channel platform provides consumers with easy-to-use, flexible and secure electronic bill payment experiences through their preferred payment channel and type. Paymentus' proprietary Instant Payment Network TM, or IPN, extends our reach by connecting our IPN partners' platforms and tens of thousands of billers to our integrated billing, payment, and reconciliation capabilities. For more information, please visit www.paymentus.com.
CATEGORY: EARNINGS NEWS
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
NYSE Content Advisory: Pre-market update + Figma valued at over $19 billion in IPO
NEW YORK, July 31, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Kristen Scholer delivers the pre-market update on July 31st Equities are catching a bid early Thursday after decent earnings reports from tech giants Microsoft and Meta. Apple and Amazon report their earnings after today's market close. Figma, which provides browser-based design software, raised $1.2 billion after pricing nearly 37 million shares at $33 each. The price was above an upwardly revised range and valued Figma at more than $19 billion. Shoulder Innovations priced five million shares at $15 each in its IPO. The company is a commercial stage shoulder surgery focused Medtech founded in 2009. Opening BellFigma (NYSE: FIG) celebrates its initial public offering Closing BellShoulder Innovations (NYSE: SI) celebrates its initial public offering Click here to download the NYSE TV App View original content to download multimedia: SOURCE New York Stock Exchange Sign in to access your portfolio
Yahoo
14 minutes ago
- Yahoo
Mastercard rises 2% premarket on Q2 earnings, revenue beat
-- Mastercard shares rose 2% in premarket trading after the payments company posted better-than-expected second-quarter earnings and revenue on the back of robust consumer spending. Adjusted earnings per share came in at $4.15, topping the consensus estimate of $4.03. Revenue for the quarter reached $8.13 billion, ahead of expectations of $7.93 billion. The company said net revenue grew 17% year-over-year, or 16% on a currency-neutral basis, driven by continued growth in consumer spending and cross-border volumes. CEO Michael Miebach highlighted recent business wins, including the extension of its exclusive partnership with American Airlines (NASDAQ:AAL). 'We're well positioned for the opportunities ahead and continue to drive new innovation like the Mastercard (NYSE:MA) Collection and Mastercard Agent Pay,' Miebach said. Related articles Mastercard rises 2% premarket on Q2 earnings, revenue beat These Under-the-Radar Stocks Offer Better Risk-Reward Ratio Than Nvidia If Powell goes, does Fed trust go with him? Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14 minutes ago
- Yahoo
Should You Invest in Penumbra (PEN)?
Baron Funds, an investment management company, released its 'Baron Health Care Fund' second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund declined 5.06% (Institutional Shares) in the quarter, against a challenging backdrop for the broader Health Care sector, compared to a 6.19% decline for the Russell 3000 Health Care Index (benchmark) and a 10.99% gain for the Russell 3000 Index (the Index). In addition, please check the fund's top five holdings to know its best picks in 2025. In its second-quarter 2025 investor letter, Baron Health Care Fund highlighted stocks such as Penumbra, Inc. (NYSE:PEN). Headquartered in Alameda, California, Penumbra, Inc. (NYSE:PEN) designs and manufactures medical devices. The one-month return of Penumbra, Inc. (NYSE:PEN) was 1.25%, and its shares gained 48.44% of their value over the last 52 weeks. On July 30, 2025, Penumbra, Inc. (NYSE:PEN) stock closed at $254.21 per share, with a market capitalization of $9.914 billion. Baron Health Care Fund stated the following regarding Penumbra, Inc. (NYSE:PEN) in its second quarter 2025 investor letter: "We added to our position in Penumbra, Inc. (NYSE:PEN), a medical device company that manufactures mechanical thrombectomy devices to remove clots. We think Penumbra's products are differentiated because of their computer assisted vacuum thrombectomy (CAVT) technology. CAVT utilizes algorithms to modulate the aspiration power depending on if a clot is detected, and to control a separate valve that injects saline to reduce friction between the clot and catheter. This maximizes clot removal while decreasing risk of blood loss. For U.S. thrombectomy, we see a market opportunity for over 1 million procedures a year across stroke and peripheral vascular, with a total addressable market (TAM) north of $8 billion. Of this TAM, Penumbra is only high single digits percentage penetrated in 2024. We are looking forward to this mechanism rolling out in the stroke setting (the Thunderbolt product which is in development). In addition, the company is seeing strong momentum in the venous setting already with their Flash product. We think this momentum could accelerate if the Storm-PE trial, which completed enrollment during the quarter, demonstrates superiority of Penumbra's CAVT plus anticoagulation versus anticoagulation alone (the current standard of care) in intermediate-high risk pulmonary embolism patients. The trial could change the treatment paradigm for pulmonary embolism." A close-up view of a technician wearing protective gloves while installing a mechanical thrombectomy system. Penumbra, Inc. (NYSE:PEN) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 47 hedge fund portfolios held Penumbra, Inc. (NYSE:PEN) at the end of the first quarter, which was 35 in the previous quarter. In the second quarter of 2025, Penumbra, Inc. (NYSE:PEN) reported revenue of $339.5 million, marking year-over-year increase of 13.4% on a reported basis and 12.7% on a constant currency basis. While we acknowledge the potential of Penumbra, Inc. (NYSE:PEN) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Penumbra, Inc. (NYSE:PEN) and shared the list of best mid-cap healthcare stocks to buy according to hedge funds. Baron Health Care Fund initiated a position in Penumbra, Inc. (NYSE:PEN) during Q1 2025. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
